SB-269970
SB-269970 is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3. SB-269970 exhibits >50-fold selectivity against other 5-HT receptors[1][2].
Product Specifications
CAS Number
201038-74-6
UNSPSC
12352005
Target
5-HT Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/SB-269970.html
Purity
98.78
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC1=CC=CC(S(=O)(N2[C@@H](CCN3CCC(C)CC3)CCC2)=O)=C1
Molecular Formula
C18H28N2O3S
Molecular Weight
352.49
References & Citations
[1]Hagan JJ, et al. Characterization of SB-269970-A, a selective 5-HT (7) receptor antagonist. Br J Pharmacol. 2000 Jun;130 (3) :539-48.|[2]Roberts C, et al. The effect of SB-269970, a 5-HT (7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol. 2001 Apr;132 (7) :1574-80.|[3]Nikiforuk A, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013 Jun 11;8 (6) :e66695.|[4]Monti JM, et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 2008 Aug 22;191 (2) :184-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
5-HT7 Receptor; MUC3
Citation 01
J Physiol. 2025 Sep;603 (17) :4723-4745.|Protein Cell. 2019 Mar;10 (3) :178-195.|Authorea. September 19, 2022.|Cancer Lett. 2024 Aug 1:217150.|Int J Biol Sci. 2024 Aug 19;20 (11) :4476-4495.|Neuron. 2025 Jun 18;113 (12) :1983-1997.e7.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
